• Tigermed formed a strategic alliance with Veeda Lifesciences to build a unified China-India clinical research platform for global drug development.
• Structure centers on a single contract, single point of accountability, harmonized data standards, unified governance for multi-country clinical trials.
• Partnership targets faster study start-up, quicker enrollment, larger patient access across China and India for multi-regional trial execution.
• Combined footprint includes Tigermed’s ICH-GCP network of 1,500+ China trial sites, Veeda’s USFDA, EMA, CDSCO-compliant capabilities in India.
• Alliance includes aligning digital platforms, AI-enabled systems to improve trial efficiency, support concurrent global regulatory submissions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou Tigermed Consulting Co. Ltd. published the original content used to generate this news brief on September 03, 2026, and is solely responsible for the information contained therein.